european end-to-end CDMO company, pharma services
  • About us
    • History
    • Company bodies
    • Team
    • EU grants
    • Requests for Proposal
    • Sustainability
    • Bussines strategy
    • Quality policy
  • Services
    • Drug Substance Manufacturing
    • Fill & Finish
    • Gene to Vial: End-to-End Development
    • Process Development
    • Analytics 
    • Cell Line Development & Banking
  • Science Hub
    • Science News
    • Articles
  • News & Events
    • Press releases
    • Events
    • Content to download
  • Investors
    • Corporate documents
    • Shareholders and shares
    • Periodic reports
    • Current reports
    • Sustainability reports
    • Corporate governance at Mabion
    • Financial data
    • For Investors
    • Calendar
  • Contact us
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • EN
    • PL
  • Science News
  • Articles

Articles

Topic
All Analytics Antibody-drug conjugates Bioanalytics Biologics Biosimilars Biostatistics Cancer Cell culture Clinical trials Contamination Drug development Drug product Drug substance EMA FDA GMP Mabion Manufacturing Microbiology Proteins Regulatory Vaccines Veterinary biologics
leading european cdmo

Leading European CDMO for Drug Product Manufacturing

Drug development, Drug product, Manufacturing

antibodies development best practices

Antibodies Development Best Practices for CDMO Collaboration

Drug development, Manufacturing, Monoclonal antibody

UV-VIS spectrometry for protein concentration analysis

UV-VIS Spectrometry for Protein Concentration Analysis: Principles and Applications 

Analytics, Biologics, Proteins

Host Cell Proteins

Qualitative analysis of Host Cell Proteins using mass spectrometry

Analytics, Drug development, Drug product, Drug substance

CDMO analytical expertise

Does Your CDMO Have An Analytical Edge?

Analytics, Biosimilars, Mabion

Innovative biologics that are expected to be approved in 2025

Innovative biologics – expected drug approvals in 2025

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines

Previous 1 … 4 5

Contact

Find out how we may support your business.

info@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • Services
    • Investors
    • News&Events
    • Contact us

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Powered by

    Veneo